• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Evening-dose immune checkpoint inhibitors were associated with worse survival outcomes

byKassandra McFarlaneandSze Wah Samuel Chan
November 22, 2021
in Dermatology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Receiving at least 20% of infusions after 1630h was associated with decreased overall survival in patients treated with immune-checkpoint inhibitors for metastatic melanoma

2. Both progression-free survival and disease response were worse in patients receiving at least 20% of infusions after 1630h.

Evidence Rating Level: 2 (Good)

Study Rundown: The immune system has circadian rhythm variability, such that weaker responses are noted in the evening. This study examined the outcome on overall survival (OS), progression-free survival (PFS), and disease response in patients receiving checkpoint inhibitor infusion treatment for stage IV melanoma at different times of the day. Evening was considered to begin at 1630h. Patients receiving a minimum of 20% of their treatment after 1630h were found to have reduced OS, with 5 year OS rates for these patients at 49% as compared to 68% for patients who had less than 20% evening treatments. PFS at 1 year in patients with a greater number of evening infusions was 40%, compared with 56% for patients with fewer evening infusions. Additionally, there was a decreased rate of disease response for patients receiving more evening infusions compared to patients receiving less (22% vs. 34%). The most common adverse events associated with checkpoint inhibitor treatment were colitis, hepatitis, and hypophysitis. No deaths due to treatment were reported. Limitations to the study include the retrospective format, the exclusion of patients receiving less than 4 infusions, as well as restriction of the study to one site. Additionally, the study results may not be applicable in all clinical scenarios due to variation of treatment sequence and duration for each patient. Overall, patients with stage IV melanoma may benefit from daytime, rather than evening, infusions of immune checkpoint inhibitors.

Click to read the study in The Lancet Oncology

Click to read an accompanying editorial in The Lancet Oncology

Relevant Reading: Circadian rhythms in adaptive immunity

RELATED REPORTS

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

#VisualAbstract: Time-of-infusion with immunotherapy may impact survival outcomes for patients with advanced melanoma

#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors

In-Depth [retrospective cohort]: This retrospective cohort study based out of one site in the United States recruited 299 adult patients with stage IV melanoma who received at least 4 infusions of immune checkpoint inhibitor therapy (nivolumab, pembrolizumab, ipilimumab, or a combination). Total and 5 year overall survival (OS) were primary outcomes, with both progression-free survival (PFS) and disease response being secondary outcomes. Analysis of all 299 patients found a crude OS hazard ratio of 1.31 (95% confidence interval (CI), 1.00-1.71) for each additional 20% infusion received in the evening. A greater number of evening infusions was also associated with reduced PFS at 40% (95% CI, 30-54%) compared to those with fewer at 56% (95% CI, 50-63%). Disease response was also reduced in patients with more evening infusions (22%) compared to those with fewer (34%). Using a propensity score-matched analysis and multivariable adjustment, infusions in the evening were associated with a decreased OS (HR 2.04, 95% CI, 1.04-4.00, p = 0.038). Five year OS for patients receiving at least 20% of their treatment in the evening was 49% (95% CI, 31-76%) compared to 68% (95% CI, 53-86%) for patients with fewer than 20%. During treatment, 18% of 299 patients experienced colitis, 9% experienced hepatitis, and 5% had hypophysitis. No treatment related-deaths were recorded.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced melanomachronotherapyimmune checkpoint inhibitors (ICI)
Previous Post

Initial therapy with non-pharmacological agents may be preferable for lower back pain

Next Post

Evorpacept as single-agent or combination pembrolizumab or trastuzumab shows promise in the treatment of advanced solid tumours

RelatedReports

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers
StudyGraphics

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

April 13, 2022
#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer
StudyGraphics

#VisualAbstract: Time-of-infusion with immunotherapy may impact survival outcomes for patients with advanced melanoma

February 16, 2022
#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors
StudyGraphics

#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors

January 21, 2022
#VisualAbstract: Acral lentiginous melanoma may be associated with higher rates of sentinel lymph node positivity compared to other melanoma subtypes
StudyGraphics

#VisualAbstract: Immune checkpoint inhibitors are equally effective for younger and older patients with relapsed or metastatic head and neck squamous cell carcinomas

January 12, 2022
Next Post
Age and number of islet autoantibodies associated with diabetes risk

Evorpacept as single-agent or combination pembrolizumab or trastuzumab shows promise in the treatment of advanced solid tumours

UTI associated with increased risk of preeclampsia

Increased cardiorespiratory fitness may lower high blood pressure in children

Intrapartum serum prolactin may predict risk of postpartum diabetes

Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.